DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteitis deformans — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteitis deformans maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteitis deformans is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
optineurin (OPTN) — OPTN is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9B0B · 1.7 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
Osteitis deformans, also called Paget’s disease, was first described in 1873 and again in 1877, and its cause remains unknown. By 1934, more than three hundred cases had been reported in the literature, but the authors of that year observed thirty-four cases within four years and suggested the disease was much commoner than previously supposed, with the increasing use of roentgenography as the probable explanation. The disease typically affects patients over 40 years of age, involving the skull, vertebrae, femur, and leg bones, though it may be confined to one bone. In a 1955 report, a single case was followed for twenty-one years, allowing long-term observation of head circumference enlargement and alkaline phosphatase blood levels, but no treatment was described. A 1940 paper noted that the cause was unknown, with some authors proposing a vascular origin such as endarteritis, possibly embolic, because the lesions resemble the distribution of carcinomatous metastases in bone.
Neurologic complications are unusual but may be underdiagnosed. A 1953 report described two cases of paraplegia due to spinal cord compression from Paget’s disease of the spinal column, noting that this complication probably occurs more often than the literature indicates because it arises in an age group where accurate neurological assessments are rarely made. The same paper stated that involvement of the spinal column is frequent, but compression of the spinal cord is unusual.
A 1996 pathomorphologic study of biopsy and operative specimens from 39 patients who underwent surgery between 1958 and 1995 identified three stages of disease development: an osteolytic stage with marked bone resorption, a remodelling stage combining disturbance of bone resorption and new bone formation, and an attenuation stage where both resorption and formation stop. The authors stated that drugs inhibiting bone tissue resorption are most expedient in the first and second stages. No drug names, response rates, survival data, or results from any therapeutic trial are provided in any of these abstracts. What is still missing is any controlled trial of a specific inhibitor of bone resorption, a clear definition of which patients would benefit from such treatment, and the funding to conduct prospective studies that measure functional outcomes rather than only pathological staging.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Internal Medicine · 1934 · 30 citations
OSTEITIS DEFORMANS
AbstractCzerny,<sup>1</sup>in 1873, first used the term "osteitis defromans" to describe softening and deformity of the tibia and fibula in a young soldier. Paget,<sup>2</sup>however, was unaware of this when he published his classic description in 1877 and suggested the term "osteitis defromans" because of his belief in the inflammatory nature of the lesion. Since that time, Roberts and Cohen<sup>3</sup>stated, more than three hundred cases of the disease have been described. In view of the fact that within four years we have observed thirty-four cases, it would appear that the disease is much commoner than was hitherto supposed. The increasing use of roentgenography is probably the explanation. The present investigation, originally commenced in 1926 as an effort to ascertain the frequency of neurologic changes in osteitis deformans, expanded into a more comprehensive clinical and biochemical investigation. <h3>REPORT OF CASES</h3><h3>Case 1.</h3> —<i>History</i>.—F. N., a
Paraplegia Due to Paget's Disease (Osteitis Deformans)
AbstractOsteitis deformans, or Paget's disease, may affect any part of the skeleton in those of older years. While involvement of the spinal column is frequent, it is unusual for compression of the spinal cord to be produced. It is probable that this complication is com- moner than the literature would indicate, as it occurs in an age group in which accurate assessments of the nervous system are rarely made. Two cases are described and their relationship to the usual pattern of the disease discussed.
A M A Archives of Internal Medicine · 1955 · 5 citations
PAGET'S DISEASE (OSTEITIS DEFORMANS) FOLLOWED FOR TWENTY-ONE YEARS
AbstractTHE CASE briefly reported here has been under our observation for 21 years, thus offering an opportunity to make longterm observations, especially on the rate of enlargement of the head circumference and on the alkaline phosphatase blood levels. A summary of our present knowledge of osteitis deformans is worth restating, and it is briefly as follows. <h3>REVIEW OF OSTEITIS DEFORMANS</h3> Osteitis deformans * is more important in the differential diagnosis of musculoskeletal disorders than is usually recognized. It commonly causes deformity in one or more of the long bones, and, as a result of the deranged body mechanics, may result in joint pain and disability simulating some forms of arthritis. The pathology may also involve the joint structures themselves. The hip joint, directly or indirectly, is the one most commonly involved. In spite of these clinical manifestations, and probably because the disease starts so insidiously, the diagnosis is often made accidentally, in
Archives of Otolaryngology - Head and Neck Surgery · 1940 · 4 citations
PAGET'S DISEASE OF THE BONES OF THE SKULL WITH OBLITERATION OF THE SINUSES
AbstractPaget's disease, or osteitis deformans, first described in 1877, is a disease of unknown cause, usually affecting a number of bones and occurring in patients over 40 years of age. It may be 1 a general disorder in which at present only the osseous changes are known. Formerly considered rare, it is known to be merely unusual, and with more roentgenograms the disease, no doubt, will be recognized oftener, particularly in its earlier stages. Osteitis deformans affects especially the skull, vertebrae and bones of the leg although it may be confined to one bone. The sacrum, spinal column, femur and cranium are oftenest affected, 2 but the disease may commence in the skull or maxilla. Although the cause is unknown, it is thought by some that the disease has a vascular origin (endarteritis), possibly embolic, so closely do the lesions resemble the distribution of carcinomatous metastases in bone. Others, because of the
N N Priorov Journal of Traumatology and Orthopedics · 1996 · 0 citations · open access
Patho- morphologic Peculiarities of the Stages of Osteitis Deformans Develkopment (Paget’s Disease)
AbstractPathomorphologic examinations of the biopsy and operative specimens were performed in 39 patients with osteitis deformans who underwent surgery at the department of Bone Pathology in Adults (CITO) during the period fron 1958 to 1995. On the basis of the personal and literature data the authors underlined three stages of the osteitis deformans development that differed by the pathologic peculiarities and activity of the pathologic process: 1st stage - stage of osteolysis characterizing by marked bone resorption; 2nd stage - stage of remodelling characterizing by the combination of disturbance process and formation of new bone; 3rd stage - stage of the attenuation of pathologic process during which the resorption and new bone formation stopped. Application of drugs that inhibit bone tissue resorption is the most expedient in the 2nd and especially in the 1st stage of the disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
